ImmuCell Corporation APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
ImmuCell Corporation (ICCC) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $66.71 thousand for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-14.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2025-08-14
- ImmuCell Corporation apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $66.71K, a 31.94% decline year-over-year.
- ImmuCell Corporation apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-03-31 was $52.22K, a 35.62% decline year-over-year.
- ImmuCell Corporation apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2024-12-31 was $68.86K, a 31.59% decline year-over-year.
- ImmuCell Corporation apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2024-09-30 was $77.56K, a 19.58% decline year-over-year.
- ImmuCell Corporation apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $325.55K, a 11.74% decline from fiscal 2023.
- ImmuCell Corporation apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $368.87K, a 38.54% increase from fiscal 2022.
- ImmuCell Corporation apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $266.24K.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2025-06-30 | $66.71K 10-Q · filed 2025-08-14 | $118.93K 10-Q · filed 2025-08-14 | $187.79K derived: sum of 3 quarters · filed 2025-08-14 | $265.35K derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | $52.22K 10-Q · filed 2025-05-14 | $121.08K derived: sum of 2 quarters · filed 2025-05-14 | $198.63K derived: sum of 3 quarters · filed 2025-05-14 | $296.66K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-12-31 | $68.86K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $146.42K derived: sum of 2 quarters · filed 2025-03-28 | $244.44K derived: sum of 3 quarters · filed 2025-08-14 | $325.55K 10-K · filed 2025-03-28 |
| 2024-09-30 | $77.56K 10-Q · filed 2024-11-13 | $175.58K derived: sum of 2 quarters · filed 2025-08-14 | $256.69K 10-Q · filed 2024-11-13 | $357.35K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-06-30 | $98.02K 10-Q · filed 2025-08-14 | $179.13K 10-Q · filed 2025-08-14 | $279.79K derived: sum of 3 quarters · filed 2025-08-14 | $376.22K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $81.11K 10-Q · filed 2025-05-14 | $181.77K derived: sum of 2 quarters · filed 2025-05-14 | $278.20K derived: sum of 3 quarters · filed 2025-05-14 | $353.86K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $100.66K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $197.09K derived: sum of 2 quarters · filed 2025-03-28 | $272.75K derived: sum of 3 quarters · filed 2025-03-28 | $368.87K 10-K · filed 2025-03-28 |
| 2023-09-30 | $96.43K 10-Q · filed 2024-11-13 | $172.09K derived: sum of 2 quarters · filed 2024-11-13 | $268.21K 10-Q · filed 2024-11-13 | $333.60K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $75.66K 10-Q · filed 2024-08-13 | $171.77K 10-Q · filed 2024-08-13 | $237.17K derived: sum of 3 quarters · filed 2024-08-13 | $322.29K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $96.12K 10-Q · filed 2024-05-14 | $161.51K derived: sum of 2 quarters · filed 2024-05-14 | $246.63K derived: sum of 3 quarters · filed 2024-05-14 | |
| 2022-12-31 | $65.39K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $150.52K derived: sum of 2 quarters · filed 2024-04-01 | $266.24K 10-K · filed 2024-04-01 | |
| 2022-09-30 | $85.12K 10-Q · filed 2023-11-13 | $200.85K 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |